There are several attempts reported in literature on treatment of CD by inhibiting gliadin-induced inflammatory responses at intracellular or submucosal level, such as zonulin antagonist [12], tissue transglutaminase inhibitors [13], peptide vaccine [14], and NKG2D/MICA blocker [15]. Here, TGM2 is linked to Cowden disease.